






TAVI vs surgery in women: 1-year pooled outcomes from the RHEIA and PARTNER 3 trials

Didier Tchetché *et al.* Transcatheter vs surgical aortic valve replacement in women: A pooled analysis of the RHEIA and PARTNER 3 trials. Presented at TCT 29 October 2024, Washington, DC, USA.



Study design	Device(s) used	THV distribution	Locations	Key patient demographics
 Randomised, controlled vs sAVR (1:1) N = 712	 SAPIEN 3 valve SAPIEN 3 Ultra valve vs any commercially available surgical valve	 20 mm: 5.6% 23 mm: 65.4% 26 mm: 26.1% 29 mm: 2.9%	 13 countries across the USA and Europe	 Mean age: TAVI: 73.4 years sAVR: 73.3 years



The largest all-woman analysis in symptomatic, severe AS patients
The Edwards SAPIEN 3 platform: Outperforming for women*



*TAVI with the SAPIEN 3 and SAPIEN 3 Ultra valves was proven superior to surgery on the composite primary endpoint of death, stroke or rehospitalisation at 1 year in female patients

The SAPIEN 3 platform: Consistently excellent outcomes in female patients^{1,2}

Key patient outcomes included: **all-cause mortality, stroke and rehospitalisation**





Edwards



Excellent performance of the SAPIEN 3 platform across age and annulus ranges

Subgroups (n)	Hazard ratio (95% CI)	Interaction p value*
Age		0.60
≤75 years (472)	0.47 [0.28–0.77]	
>75 years (240)	0.60 [0.30–1.22]	
Systolic annular area†		0.71
≤430 mm ² (466)	0.57 [0.34–0.95]	
>430 mm ² (228)	0.48 [0.23–0.97]	


*Cox model interaction p value of the treatment and respective subgroups is calculated using Wald's test. †Systolic annular area subgroup analysis is based on the VI population.



Excellent haemodynamic performance at 1 year for the SAPIEN 3 platform, with very low rates of paravalvular leak



Quality of life is significantly improved at 1 month and sustained at 1 year



References

- Mack MJ, Leon MB, Thourani VH et al. Transcatheter aortic valve replacement with a balloon-expandable valve in low-risk patients. *N Engl J Med.* 2019; **380**: 1695–705.
- Mack MJ, Leon MB, Thourani VH et al. Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years. *N Engl J Med.* 2023; **389**: 1949–60.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, PARTNER, PARTNER 3, SAPIEN, SAPIEN 3 and SAPIEN 3 Ultra are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks or service marks are the property of their respective owners.

© 2024 Edwards Lifesciences Corporation. All rights reserved. PP–EU-9390 v1.0

Edwards Lifesciences Sàrl • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com



Edwards